で公開中です！ 詳しく見る
CPRXのアイコン

Catalyst Pharmaceutical
CPRX

上場廃止済み

CPRXは2026年7月14日に上場廃止となりました。

ランキングに戻る
 

概要： Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

従業員数： 182

ヘルスケア バイオテクノロジー

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 0%
ニュートラル 0%
ネガティブ 0%
ポジティブ
Reuters
3 か月前
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker ​Catalyst Pharmaceuticals in a $4.1 billion deal involving ‌Italian state lender CDP.
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
ニュートラル
GlobeNewsWire
3 か月前
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
ポジティブ
MarketBeat
3 か月前
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
ポジティブ
Zacks Investment Research
3 か月前
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
ニュートラル
GlobeNewsWire
3 か月前
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses
ニュートラル
Business Wire
3 か月前
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t.
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRX
ポジティブ
Zacks Investment Research
4 か月前
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
ポジティブ
Zacks Investment Research
4 か月前
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
ポジティブ
Zacks Investment Research
4 か月前
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term
ポジティブ
Zacks Investment Research
5 か月前
CPRX or UTHR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
CPRX or UTHR: Which Is the Better Value Stock Right Now?
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています